Matching articles for "Pneumovax23"
Capvaxive – A 21-Valent Pneumococcal Conjugate Vaccine
The Medical Letter on Drugs and Therapeutics • October 14, 2024; (Issue 1713)
The FDA has licensed Capvaxive (PCV21; Merck),
a 21-valent pneumococcal conjugate vaccine, for
prevention of invasive pneumococcal disease (IPD)
and pneumococcal pneumonia in adults. Four other
pneumococcal...
The FDA has licensed Capvaxive (PCV21; Merck),
a 21-valent pneumococcal conjugate vaccine, for
prevention of invasive pneumococcal disease (IPD)
and pneumococcal pneumonia in adults. Four other
pneumococcal vaccines are currently available in the
US: Prevnar 20 (PCV20), Vaxneuvance (PCV15), and
Prevnar 13 (PCV13) are conjugate vaccines licensed
for use in persons ≥6 weeks old, and Pneumovax 23
(PPSV23) is a pneumococcal polysaccharide vaccine
licensed for use in persons ≥2 years old (see Table 1).
Adult Immunization
The Medical Letter on Drugs and Therapeutics • October 17, 2022; (Issue 1661)
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these...
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these vaccine-preventable diseases, but many
adults remain susceptible. Recommendations for
vaccination against COVID-19, seasonal influenza,
and monkeypox and vaccination of travelers have
been reviewed separately.
Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance
The Medical Letter on Drugs and Therapeutics • November 29, 2021; (Issue 1638)
The FDA has licensed two new pneumococcal
conjugate vaccines (PCVs) for prevention of invasive
pneumococcal disease in adults: Prevnar 20 (PCV20;
Pfizer), which contains antigens from 20 serotypes...
The FDA has licensed two new pneumococcal
conjugate vaccines (PCVs) for prevention of invasive
pneumococcal disease in adults: Prevnar 20 (PCV20;
Pfizer), which contains antigens from 20 serotypes of
pneumococcus, and Vaxneuvance (PCV15; Merck),
which contains antigens from 15 serotypes. Two
other pneumococcal vaccines are available in the
US: Prevnar 13 (PCV13; Pfizer), a 13-valent conjugate
vaccine licensed for use in persons ≥6 weeks old,
and Pneumovax 23 (PPSV23; Merck), a 23-valent
pneumococcal polysaccharide vaccine licensed for
use in persons ≥2 years old.
Vaccines for Travelers
The Medical Letter on Drugs and Therapeutics • November 19, 2018; (Issue 1560)
Persons planning to travel outside the US should be
up to date on routine vaccines and, depending on their
destination, duration of travel, and planned activities,
may also receive certain travel-specific...
Persons planning to travel outside the US should be
up to date on routine vaccines and, depending on their
destination, duration of travel, and planned activities,
may also receive certain travel-specific vaccines.
Tickborne encephalitis and dengue vaccines, which
are not available in the US, are reviewed in a separate
article available online. Detailed advice for travel to
specific destinations is available from the Centers for
Disease Control and Prevention (CDC) at www.cdc.gov/travel/destinations/list. Recommendations for
administration of vaccines as part of routine adult
immunization are discussed in a separate issue.
Adult Immunization
The Medical Letter on Drugs and Therapeutics • May 7, 2018; (Issue 1546)
The US Advisory Committee on Immunization Practices
(ACIP) recommends routine use of the following
vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with...
The US Advisory Committee on Immunization Practices
(ACIP) recommends routine use of the following
vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with acellular
pertussis (Tdap), measles/mumps/rubella (MMR),
varicella (VAR), herpes zoster (RZV; ZVL), human
papillomavirus (HPV), and pneumococcal conjugate
(PCV13) and polysaccharide (PPSV23) vaccines. For
adults with certain medical conditions or occupational,
behavioral, or other risk factors, hepatitis A (HepA),
hepatitis B (HepB), meningococcal (MenACWY; MenB),
and Haemophilus influenzae type b (Hib) vaccines are
also recommended. Recommendations for vaccination
against seasonal influenza and vaccination of travelers
are reviewed separately.
Expanded Table: Some Vaccines Recommended for Use in Adults (online only)
The Medical Letter on Drugs and Therapeutics • May 7, 2018; (Issue 1546)
...
View the Expanded Table: Some Vaccines Recommended for Use in Adults
Addendum: PCV13 for Adults 65 Years and Older
The Medical Letter on Drugs and Therapeutics • October 12, 2015; (Issue 1479)
In 2014, the US Advisory Committee on Immunization
Practices (ACIP) recommended that all adults 65 years
old and older being vaccinated against pneumococcus for
the first time receive the pneumococcal...
In 2014, the US Advisory Committee on Immunization
Practices (ACIP) recommended that all adults 65 years
old and older being vaccinated against pneumococcus for
the first time receive the pneumococcal conjugate vaccine
(PCV13) followed 6 to 12 months later by the pneumococcal
polysaccharide vaccine (PPSV23)(Med Lett Drugs Ther 2014; 56:102). In June 2015, the ACIP
changed the recommended interval between the two
vaccines to >1 year for immunocompetent adults ≥65
years old (MMWR Morbid Mortal Wkly Rep 2015; 674:944).
Separating the vaccines by a year or more may improve
the immune response to the serotypes in both vaccines. If
a dose of PPSV23 is given earlier than the recommended
interval, it does not need to be repeated.
Download complete U.S. English article
Download complete U.S. English article
In Brief: PCV13 for Adults 65 Years and Older
The Medical Letter on Drugs and Therapeutics • October 13, 2014; (Issue 1453)
The US Advisory Committee on Immunization Practices (ACIP) now recommends routine immunization with 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13), in addition to the 23-valent pneumococcal...
The US Advisory Committee on Immunization Practices (ACIP) now recommends routine immunization with 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13), in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23), for all adults ≥65 years old.1
An unpublished, randomized, double-blind trial (CAPiTA) in about 85,000 adults ≥65 years old found that vaccination with PCV13 reduced first episodes of vaccine-type community-acquired pneumonia and invasive pneumococcal disease by 46% and 75%, respectively, compared to placebo.2
Adults ≥65 years old who previously received ≥1 dose of PPSV23 should also receive PCV13, but at least one year after the last dose of PPSV23. For those receiving the pneumococcal vaccine for the first time, PCV13 should be given first, followed 6-12 months later by PPSV23. PCV13 can be given at the same time as an inactivated influenza vaccine. Currently, Medicare only pays for one lifetime dose of a pneumococcal vaccine for healthy patients.
Download complete U.S. English article
An unpublished, randomized, double-blind trial (CAPiTA) in about 85,000 adults ≥65 years old found that vaccination with PCV13 reduced first episodes of vaccine-type community-acquired pneumonia and invasive pneumococcal disease by 46% and 75%, respectively, compared to placebo.2
Adults ≥65 years old who previously received ≥1 dose of PPSV23 should also receive PCV13, but at least one year after the last dose of PPSV23. For those receiving the pneumococcal vaccine for the first time, PCV13 should be given first, followed 6-12 months later by PPSV23. PCV13 can be given at the same time as an inactivated influenza vaccine. Currently, Medicare only pays for one lifetime dose of a pneumococcal vaccine for healthy patients.
- S Tomczyk et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63:822.
- M Bonten et al. Community acquired pneumonia immunisation trial in adults (CAPITA). Abstract #O-015. International Symposium on Pneumococci and Pneumococcal Diseases 2014. Available at: http://isppd.meetingxpert.net. Accessed October 2, 2014.
Download complete U.S. English article